Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.
VentureMed Group, Ltd., a medical device company based in northwest Ohio, has received 510(k) clearance from the U.S. Food and Drug Administration for the commercial distribution of a new surgical device for treating peripheral artery disease (PAD).
The dangers of arterial thrombosis - the formation of blood clots that can block arteries and cause illness or death - can escalate through a vicious cycle of coagulation and inflammation.
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.
Rush Oak Park Hospital is the first hospital in the surrounding area to acquire and use a newly approved technology that allows vascular surgeons to see in real-time the plaque they are removing during an atherectomy, a minimally invasive procedure that helps treat peripheral artery disease (PAD).
Long-term results from the ENESTnd trial indicate a favourable risk-benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase-chronic myeloid leukaemia diagnosis.
“Genomic medicine really needs deep learning,” these were the words of keynote speaker Brendan Frey, CEO Deep Genomics at RE-WORK’s Deep Learning in Healthcare Summit 2016.
New findings from large-scale studies of more than 3.6 million people who underwent screening for cardiovascular disease reveals that a person's age and gender affects the prevalence of certain types of peripheral vascular diseases (PVD), and that diabetes is a major risk factor for developing these diseases, even in patients without heart disease.
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania into the TOBA II clinical on October 19, 2015. This trial is to assess the safety and efficacy of a vascular implant for the treatment of dissections (tearing in the artery wall) that occur following balloon angioplasty (PTA) of the main artery in the leg.
Bioengineers and physicians at the University of California, San Diego have developed a potential new therapy for critical limb ischemia, a condition that causes extremely poor circulation in the limbs and leads to an estimated 230,000 amputations every year in North America and Europe alone to prevent the spread of infection and tissue death.
"Critical limb ischemia" (CLI) describes an advanced stage of peripheral artery disease characterized by obstruction of the arteries and a markedly reduced blood flow to the extremities. CLI identifies patients at high-risk for major amputation. The estimated annual incidence of CLI ranges between 500 and 1000 new cases out of one million people per year, with the highest rates among the elderly, smokers, and those with diabetes. CLI is considered to be a critical public health issue. Attempts at revascularization are often unsuccessful.
Renal Dynamics' third-generation Renal Denervation System received CE clearance and is now commercially available in Europe for treatment of Resistant Hypertension. The ReDy Renal Denervation System is based on a novel multi-electrode ablation technology that delivers a pre-determined RF ablation set with a single positioning.
Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces that 'Haemodynamics and Flow Modification Stents for Peripheral Arterial Disease: A Review’, co-authored by VFT’s non-executive Medical Director Graeme Houston, has been published in the Annals of Biomedical Engineering. The paper reviews the importance of haemodynamics in stent development as a method of improving patency and longevity of the stent.
Rupture of an abdominal aortic aneurysm is one of the most dramatic medical emergencies a person can face. It usually strikes without warning, killing approximately 50 percent of those who experience it before they reach a hospital. Of those who do get to a health facility alive, only about 50 percent survive.
Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.
Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal.
Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).
Resverlogix Corp. is pleased to announce that Dr. Norman Wong, chief scientific officer of Resverlogix Corp. presented new data at the European Society of Cardiology (ESC) Congress 2015 in a poster presentation titled: "RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-I/HDL."
Coffee drinking is associated with increased risk of cardiovascular events (mainly heart attacks) in young adults (18-45) with mild hypertension, according to research presented at ESC Congress today by Dr Lucio Mos, a cardiologist at Hospital of San Daniele del Friuli in Udine, Italy.
Patients with hypertension treated with acupuncture experienced drops in their blood pressure that lasted up to a month and a half, researchers with the Susan Samueli Center for Integrative Medicine have found.